中国药物经济学Issue(9)：15-16,28,3.
盐酸坦洛新缓释胶囊治疗良性前列腺增生的药物经济学评价
Pharmacoeconomic Evaluation of Tamsulosin Hydrochloride Sustained-release Capsules in the Treatment of Benign Prostatic Hyperplasia
董恒进 1王如伟 2徐春玲 3伍玲4
作者信息
- 1. 浙江大学医学部卫生政策学研究中心，浙江杭州 310058
- 2. 浙江省卫生经济学会药物经济学专业委员会，浙江杭州 310058
- 3. 浙江康恩贝制药股份有限公司，浙江杭州 310052
- 4. 杭州康恩贝制药有限公司，浙江杭州 310052
- 折叠
摘要
Abstract
Objective To explore the effect of Tamsulosin Hydrochloride Sustained-release Capsules cost for the treatment of benign prostatic hyperplasia.Methods 6 September 2007 to October 2008 hospital 238 cases of benign prostate hyperplasia patient data colection,the patients were divided into treatment group and control group according to random number table method,119 cases in each,the control group of patients taking tamsulosin hydrochloride sustained-release capsules,treatment group patients taking tamsulosin hydrochloride sustained release capsules.The cost-effectiveness of the two groups of patients was compared.Results After treatment,IPSS score of two groups of patients were significantly lower than the treatment before andQmax were significantly higher than those before treatment,differences were statisticaly significant(P<0.05);the cost of the treatment group is lower than that of control group,and from the incremental cost-effectiveness ratio,if get an effect unit, the control group than in the treatment group spend more than 98 yuan.Conclusion Integrated efficacy of tamsulosin hydrochloride sustained release capsules and tamsulosin hydrochloride sustained release capsules in the treatment of benign prostatic hyperplasiais the same,but the cost of the former is low.关键词
盐酸坦洛新缓释胶囊/盐酸坦索罗辛缓释胶囊/良性前列腺增生/药物经济学Key words
BiTan Tamsulosin Hydrochloride/HaLe Tamsulosin Hydrochloride/Benign Prostatic Hyperplasia/Pha- rmacoeconomics分类
医药卫生引用本文复制引用
董恒进,王如伟,徐春玲,伍玲..盐酸坦洛新缓释胶囊治疗良性前列腺增生的药物经济学评价[J].中国药物经济学,2015,(9):15-16,28,3.
